Nucleus Software recommends ₹12.50 final dividend; reappoints MD Vishnu R Dusad for 5 years.
Nucleus Software's Board approved Q4FY26 and FY26 financial results. A final dividend of ₹12.50 per share is recommended, subject to shareholder approval. Mr. Vishnu R Dusad has been re-appointed as Managing Director for a five-year term starting January 1, 2027.
The final dividend recommendation and MD re-appointment are significant for shareholders and company leadership, impacting investor sentiment and strategic direction.
The announcement is positive due to the recommendation of a final dividend and the re-appointment of the Managing Director, indicating stability and shareholder returns.
Nucleus Software Exports Limited announced the outcome of its Board Meeting held on May 21, 2026. The Board approved the Audited Standalone and Unaudited Consolidated Results for the Quarter ended March 31, 2026, as well as the Audited Standalone and Audited Consolidated Results for the financial year ended March 31, 2026. The Audit Committee and the Board of Directors reviewed and approved these financial statements.
In addition, the Board recommended a final dividend of ₹12.50 per equity share, representing 125% of the face value of ₹10 each, for the financial year 2025-26. This recommendation is subject to shareholder approval at the upcoming Annual General Meeting (AGM).
Furthermore, the Board approved the re-appointment of Mr. Vishnu R Dusad as the Managing Director for a term of five consecutive years, effective from January 1, 2027, until December 31, 2031. This re-appointment is also subject to shareholder approval and is in compliance with the Companies Act, 2013, and SEBI regulations.
The Board also considered and approved amendments to the Whistleblower Policy, in compliance with SEBI regulations. The amended policy is available on the company's website.
What to do with a filing like this
Nucleus Software Exports Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Nucleus Software Exports Limited. Read the original for the full detail.